Product Overview
Generic name: Adefovir dipivoxil tablets
Chinese Pinyin: Adefuweizhi Pian
Product name: Ding He
Ingredients: The main ingredient of this product is adefovir dipivoxil
Properties: This product is a film-coated tablet, white or almost white after removing the coating.
Indications: This product is suitable for the treatment of adult chronic hepatitis B patients with compensatory liver function with active replication of hepatitis B virus and continuous increase in serum amino acid transferase
Specification: 10mg*14 tablets/box
Usage and dosage: Patients must use this product under the guidance of a doctor with experience in the treatment of chronic hepatitis B. The recommended dose for adults (18-65 years old) is 10 mg once a day, orally before or after meals. The best course of treatment has not yet been determined. Do not exceed the recommended dosage. Patients should regularly monitor hepatitis B biochemical indicators, virological indicators and serum markers, at least once every 6 months
Adverse reactions: Common adverse reactions in foreign clinical studies are weakness, headache, abdominal pain, nausea, (gastrointestinal) bloating, diarrhea and indigestion. The adverse reactions in domestic clinical studies are leukopenia (mild), diarrhea (mild) and hair loss (moderate)
Contraindications: Adefovir dipivoxil is forbidden to be used in patients who have been confirmed to be allergic to any component of this product
Note: 1. Patients who stop hepatitis B treatment will experience acute exacerbations of hepatitis, including stopping the use of adefovir dipivoxil. Therefore, patients who stop hepatitis B treatment should closely monitor liver function, and if necessary, anti-hepatitis B treatment should be restarted. 2. For patients with renal dysfunction or potential risk of renal dysfunction, chronic treatment with adefovir dipivoxil can cause nephrotoxicity. These patients should closely monitor renal function and adjust the dose appropriately. 3. Before treatment with adefovir dipivoxil, all patients should be tested for human immunodeficiency virus (HIV) antibodies. The use of anti-hepatitis B treatment drugs, such as adefovir dipivoxil, will have an effect on unknown or untreated HIV carried by chronic hepatitis B patients, and HIV resistance may appear. 4. Single use of nucleoside analogues or combination of other antiretroviral drugs can cause lactic acidosis and severe hepatomegaly with steatosis, including fatal events. Because the risk to developing human embryos is still unclear, it is recommended that women of childbearing age treated with adefovir dipivoxil take effective contraceptive measures.
Drug interactions: 1. Combination with salicylic acid, sulfonamides, phenylbutazone, antituberculosis drugs, tetracyclines, monoamine oxidase inhibitors, b-receptor blockers, chloramphenicol, dicoumarins and cyclophosphamide can enhance this Product role. 2. Chlorpromazine, sympathomimetic drugs, corticosteroids, thyroid hormones, oral contraceptives and niacin preparations can reduce the blood sugar lowering effect of this product. This product can weaken the patient's tolerance to alcohol, and alcohol may also strengthen the drug The blood sugar lowering effect.
Pharmacology and Toxicology: Adefovir dipivoxil is quickly converted into adefovir in the body. At concentrations significantly higher than those observed in vivo (>4000 times), adefovir has no inhibitory effect on any of the following common human CYP450 enzymes: CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. Adefovir is not a substrate for these enzymes. However, it is not clear whether adefovir induces CYP450 enzymes. According to the results of in vitro experiments and the renal elimination pathway of adefovir, it is unlikely that adefovir, as an inhibitor or substrate, interacts with other drugs mediated by CYP450. Adefovir is excreted through the kidneys through glomerular filtration and active secretion by renal tubules. The combination of 10 mg adefovir dipivoxil with other drugs secreted by the renal tubules or drugs that change the secretion function of the renal tubules can increase the serum concentration of adefovir dipivoxil or the combined drugs. 10mg adefovir dipivoxil and 100mg lamivudine were used in combination, and the pharmacokinetic properties of the two drugs remained unchanged. Caution should be exercised when combining 10 mg adefovir dipivoxil with drugs that are actively secreted through the renal tubules, because two drugs compete for the same elimination pathway, which may cause the serum concentration of adefovir or the combined drug to increase.
Storage: Sealed and stored in a cool and dry place.
Packing: medicinal aluminum-plastic blister pack, 14 pieces/box
Validity period: 24 months
Approval number: National Medicine Standard H20080034
Company Name: Chenxin Pharmaceutical Co., Ltd.
